{"filings":[{"id":92081,"accession_number":"0001321732-26-000024","cik":1321732,"company_name":"Penumbra Inc","ticker":"PEN","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Penumbra shareholders approve merger with Boston Scientific; vote 28.6M for, 85k against","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Special meeting held May 6, 2026; 28,665,933 shares present, quorum achieved.","Merger Proposal adopted: 28,564,786 for, 85,334 against, 15,813 abstain.","Advisory compensation proposal also approved: 27,811,605 for.","Adjournment proposal deemed unnecessary after merger approval.","Closing remains subject to regulatory clearances, including HSR and non-U.S. antitrust."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":12574256337.4705,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":92080,"accession_number":"0001321732-26-000018","cik":1321732,"company_name":"Penumbra Inc","ticker":"PEN","form_type":"8-K","filed_at":"2026-05-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Penumbra Q1 revenue $374.8M (+15.6% YoY); net income $32.6M; no guidance due to pending BSX acquisition","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $374.8M, up 15.6% YoY; thrombectomy $253.9M (+12.1%), embolization & access $120.8M (+23.8%).","Gross margin 67.6% (+1.0 pp); operating income $38.2M; net income $32.6M.","Operating expenses include $9.4M acquisition-related costs for pending Boston Scientific deal.","No FY2026 guidance provided due to pending acquisition by Boston Scientific (NYSE: BSX)."],"consensus_eps_estimate":null,"consensus_eps_actual":0.82,"consensus_revenue_estimate":null,"consensus_revenue_actual":374758000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":12574256337.4705,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":102630,"accession_number":"0001321732-26-000006","cik":1321732,"company_name":"Penumbra Inc","ticker":"PEN","form_type":"8-K","filed_at":"2026-02-25T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Penumbra Q4 revenue $385.4M (+22.1%); operating income $59.2M; FY25 rev $1.4B (+17.5%)","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $385.4M for Q4, up 22.1% YoY (20.9% constant currency). US Thrombectomy $203.1M (+12.4%).","Gross margin 68.0% vs 66.8% a year ago; operating margin 15.4%.","Net income $47.3M; adjusted EBITDA $79.1M (20.5% margin).","Full year revenue $1,403.7M, up 17.5%; net income $177.7M; adjusted EBITDA $266.8M.","Embolization & access revenue grew 37.0% in Q4; international revenue up 27.7% (21.9% constant currency)."],"consensus_eps_estimate":null,"consensus_eps_actual":4.52,"consensus_revenue_estimate":null,"consensus_revenue_actual":1403665000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":12574256337.4705,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":102629,"accession_number":"0000950103-26-000523","cik":1321732,"company_name":"Penumbra Inc","ticker":"PEN","form_type":"8-K","filed_at":"2026-01-15T23:59:59+00:00","items":["1.01","2.02","7.01","9.01"],"status":"ready","headline":"Boston Scientific to acquire Penumbra: $374 cash or 3.8721 BSX shares per share; 73% cash/27% stock","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Penumbra holders elect $374 cash or 3.8721 BSX shares per share; proration targets 73.26% cash/26.74% stock.","Termination: Penumbra pays $525M if it accepts superior offer; Boston Sci pays $900M if antitrust fails.","Closing subject to Penumbra stockholder vote, HSR and foreign antitrust clearance, S-4 effectiveness, NYSE listing.","Preliminary Q4/FY2025 results released; audited financials pending, specific figures not in filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":1.0,"calibrated_materiality_score":1.0,"market_cap_usd":12574256337.4705,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118866,"accession_number":"0001321732-25-000108","cik":1321732,"company_name":"Penumbra Inc","ticker":"PEN","form_type":"8-K","filed_at":"2025-11-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Penumbra Q3 revenue $354.7M (+17.8% YoY); full-year guidance raised to $1.375-1.380B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net income of $45.9M; adjusted EBITDA $66.7M (18.8% margin).","U.S. Thrombectomy revenue $192.0M (+18.5%); U.S. VTE revenue up 34% YoY.","Gross margin improved to 67.8% vs 66.5% a year ago; operating margin 13.8%.","Full-year 2025 revenue guidance increased to $1.375B-$1.380B (15-16% growth).","Total revenue $354.7M (+17.8% or +16.9% constant currency); U.S. revenue +21.5%."],"consensus_eps_estimate":null,"consensus_eps_actual":3.32,"consensus_revenue_estimate":null,"consensus_revenue_actual":1018280000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":12574256337.4705,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":135406,"accession_number":"0001321732-25-000101","cik":1321732,"company_name":"Penumbra Inc","ticker":"PEN","form_type":"8-K","filed_at":"2025-08-27T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Penumbra promotes Shruthi Narayan to President, CEO remains Elsesser","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Shruthi Narayan, former President Interventional, becomes President effective Sept 1, 2025; reports to CEO Adam Elsesser.","Adam Elsesser, who previously held President role, continues as Chairman and CEO.","Narayan received equity grant of ~$2.5M in RSUs vesting over 4 years.","Spouse is CEO of N28 Technologies; Penumbra paid N28 ~$2M since Jan 2024 under approved agreements."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":12574256337.4705,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":135405,"accession_number":"0001321732-25-000097","cik":1321732,"company_name":"Penumbra Inc","ticker":"PEN","form_type":"8-K","filed_at":"2025-07-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Penumbra Q2 revenue $339.5M (+13.4% YoY); net income $45.3M vs prior-year loss","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $339.5M, +13.4% YoY; U.S. Thrombectomy $188.5M (+22.6%); U.S. VTE +42%.","Net income $45.3M vs loss from operations of $81.0M in Q2 2024; operating margin 12.0%.","Adjusted EBITDA $61.4M (18.1% margin); gross margin improved to 66.0% from 54.4% (ex $33.4M one-time charge)."],"consensus_eps_estimate":null,"consensus_eps_actual":2.15,"consensus_revenue_estimate":null,"consensus_revenue_actual":663595000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":12574256337.4705,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":152391,"accession_number":"0001321732-25-000093","cik":1321732,"company_name":"Penumbra Inc","ticker":"PEN","form_type":"8-K","filed_at":"2025-05-30T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"Penumbra shareholders approve board declassification and supermajority elimination","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board declassification approved by 31,773,328 votes; phase-in over 3 years, fully declassified by 2028.","Supermajority voting requirement eliminated by 31,755,837 votes; replaced with majority standard.","Class I directors Janet Leeds and Thomas Wilder elected with 29.9M and 27.2M votes for, respectively.","Advisory say-on-pay approved with 31.1M votes for (97.7% of votes cast)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":12574256337.4705,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":152390,"accession_number":"0001321732-25-000085","cik":1321732,"company_name":"Penumbra Inc","ticker":"PEN","form_type":"8-K","filed_at":"2025-04-23T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Penumbra Q1 2025 revenue $324.1M (+16.3% YoY); net income $39.2M; raises U.S. thrombectomy guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $324.1M (+16.3% YoY); U.S. Thrombectomy $187.9M (+25.0%).","Net income $39.2M; adjusted EBITDA $59.6M (18.4% margin).","Operating income $40.4M (12.4% margin); gross margin improved to 66.6% from 65.0%.","Raises U.S. Thrombectomy growth guidance to 20-21% YoY (from 19-20%); rev guidance reaffirmed $1.34-$1.36B.","International revenue down 2.5% YoY (-0.1% constant currency)."],"consensus_eps_estimate":null,"consensus_eps_actual":1.0,"consensus_revenue_estimate":null,"consensus_revenue_actual":324140000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":12574256337.4705,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":171227,"accession_number":"0001321732-25-000036","cik":1321732,"company_name":"Penumbra Inc","ticker":"PEN","form_type":"8-K","filed_at":"2025-02-21T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Penumbra director Don Kassing to retire April 1, 2025 after 17 years","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Don Kassing, board member since 2008 and Presiding Director since 2015, will retire effective April 1, 2025.","Kassing's retirement is not due to any disagreement with Penumbra.","No replacement for the board seat has been announced.","Kassing previously served as President Emeritus and President of San Jose State University."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":12574256337.4705,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":171226,"accession_number":"0001321732-25-000010","cik":1321732,"company_name":"Penumbra Inc","ticker":"PEN","form_type":"8-K","filed_at":"2025-02-18T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Penumbra Q4 adjusted revenue $321.3M (+13%); U.S. thrombectomy up 27%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Adjusted revenue (excl. Italian payback) Q4 $321.3M, up 12.9% YoY; reported revenue $315.5M (+10.8%).","GAAP net income Q4 $33.7M (10.7% margin); full-year net income $14.0M.","Adjusted EBITDA Q4 $63.7M (19.8% margin); full-year $171.0M (14.2% margin).","U.S. thrombectomy products grew 27.3% in Q4; international thrombectomy revenue declined 13.9% adjusted.","Full-year adjusted revenue $1,200.4M, up 13.4% YoY."],"consensus_eps_estimate":null,"consensus_eps_actual":0.36,"consensus_revenue_estimate":null,"consensus_revenue_actual":1194615000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":12574256337.4705,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":188200,"accession_number":"0001321732-24-000116","cik":1321732,"company_name":"Penumbra Inc","ticker":"PEN","form_type":"8-K","filed_at":"2024-10-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Penumbra Q3 revenue $301M (+11.1% YoY); U.S. thrombectomy up 21.2%; raises segment guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $301.0M, +11.1% YoY; net income $29.5M; adjusted EBITDA $56.7M (18.8% margin).","U.S. thrombectomy revenue $162.1M, +21.2% YoY; VTE franchise grew 32% vs Q3 2023.","GAAP operating income $35.4M vs $12.6M in Q3 2023; non-GAAP operating income $40.3M.","Full-year 2024 revenue reaffirmed $1.18-1.20B; U.S. thrombectomy growth expectation raised to 24-25% from 23-25%.","Wind down of Immersive Healthcare incurred $5M in one-time expenses during Q3 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.51,"consensus_revenue_estimate":null,"consensus_revenue_actual":879097000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":12574256337.4705,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":204689,"accession_number":"0001321732-24-000090","cik":1321732,"company_name":"Penumbra Inc","ticker":"PEN","form_type":"8-K","filed_at":"2024-08-13T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Penumbra announces $200M share repurchase authorization, $100M accelerated buyback","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board authorized up to $200M in stock repurchases through July 31, 2025.","$100M accelerated share repurchase (ASR) with JPMorgan Chase initiated on Aug 12, 2024.","Initial delivery of ~474,000 shares on Aug 13, 2024; final settlement expected Q3 2024.","ASR funded with cash on hand; will reduce diluted share count."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":12574256337.4705,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":204688,"accession_number":"0001321732-24-000086","cik":1321732,"company_name":"Penumbra Inc","ticker":"PEN","form_type":"8-K","filed_at":"2024-07-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Penumbra Q2 revenue $299.4M (+14.5%); loss from ops $81M on $110.3M impairment charges","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["U.S. thrombectomy revenue $153.7M, up 24.9% YoY; global thrombectomy revenue $203.5M (+25.2%).","GAAP operating loss $81.0M includes $110.3M non-cash impairment/write-down on Immersive Healthcare assets.","Non-GAAP income from operations $31.7M vs $20.3M YoY; adjusted EBITDA $46.3M (15.5% margin).","Cash/marketable investments increased $26.2M from Q1, driven by non-GAAP profitability and working capital.","Global embolization & access revenue fell 3.1% YoY to $95.9M, with international down 10.8%."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.27,"consensus_revenue_estimate":null,"consensus_revenue_actual":578058000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":12574256337.4705,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":221535,"accession_number":"0001321732-24-000075","cik":1321732,"company_name":"Penumbra Inc","ticker":"PEN","form_type":"8-K","filed_at":"2024-06-07T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Penumbra stockholders elect two Class III directors, ratify PwC, approve say-on-pay","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Adam Elsesser and Harpreet Grewal elected as Class III directors with ~86% of votes cast.","Ratification of PwC as independent auditor for FY2024 approved: 35.1M for, 57.5K against.","Advisory vote on executive compensation passed with 29.2M for, 2.1M against.","Total shares outstanding entitled to vote: 38,757,817; 35,255,367 voted at the meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":12574256337.4705,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":221534,"accession_number":"0001321732-24-000058","cik":1321732,"company_name":"Penumbra Inc","ticker":"PEN","form_type":"8-K","filed_at":"2024-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Penumbra Q1 revenue $278.7M (+15.4% YoY); U.S. thrombectomy up 35.2%; reaffirms FY24 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $278.7M, up 15.4% YoY (15.2% constant currency); U.S. thrombectomy $150.3M, +35.2%.","GAAP operating income $12.1M vs $8.0M YoY; non-GAAP operating income $19.3M.","Adjusted EBITDA $37.6M (13.5% margin); cash & investments rose $24.3M sequentially.","FY2024 guidance reaffirmed: total revenue growth 16-20%, U.S. thrombectomy growth 27-30%.","Gross margin improved to 65.0% from 62.6% on favorable product mix and productivity."],"consensus_eps_estimate":null,"consensus_eps_actual":0.28,"consensus_revenue_estimate":null,"consensus_revenue_actual":278655000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":12574256337.4705,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":241067,"accession_number":"0001321732-24-000042","cik":1321732,"company_name":"Penumbra Inc","ticker":"PEN","form_type":"8-K","filed_at":"2024-03-21T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Penumbra dismisses Deloitte, appoints PwC as auditor for FY2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Deloitte & Touche dismissed as independent auditor effective March 17, 2024.","PricewaterhouseCoopers appointed as new auditor for fiscal year ending Dec 31, 2024.","Deloitte's reports on 2023 and 2022 financials contained no adverse opinion or qualification.","No disagreements or reportable events occurred during 2023, 2022, or interim period through March 17, 2024.","Deloitte has provided a letter agreeing with the company's disclosures, filed as Exhibit 16.1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":12574256337.4705,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}